Treatment of infertility
AssigneeNna/S
InventorsChristian Grøndahl, Thomas Høst Hansen, Alexander Rübig, Christa Hegele-Hartung
Life of this patent
Estimating the term…
Abstract
In vitro fertilization can be improved by adding a meiosis activating compound.
Claims15
A method for in vitro fertilization of human oocytes, said method comprising:
- (a) treating a female patient within a consecutive period of 30 days with a hypothalamic hormone, alone or in combination with a pituitary hormone, or an agonist or antagonist thereof, or a pituitary hormone or an agonist or antagonist thereof alone;
- (b) retrieving an oocyte(s) from the patient;
- (c) maturing the oocyte(s) in vitro, wherein during said maturation the oocyte(s) are exposed to a meiosis activating substance (MAS), and wherein the meiosis activating substance is a compound having a percentage germinal vesicle breakdown which is significantly higher than a control;
- and
- (d) fertilizing the in vitro matured oocyte(s).
A pharmaceutical kit comprising in unit dosage form for in vitro fertilization, separate dosage units for sequential daily administration of a hypothalamic hormone, alone or in combination with a pituitary hormone or an agonist or antagonist thereof, or a pituitary hormone or an agonist or antagonist thereof alone, and 1 dosage unit of a meiosis activating substance (MAS) compound.
A method for treating a female patient for infertility, for improving the maturation of her oocytes, for improving the synchrony of nuclear, cytoplasmic or membraneous oocyte maturation, for improving the fertility of her oocytes, or for improving the rate of implantation by human in vitro maturation and fertilization, said method comprising:
- (a) treating the female patient within a consecutive period of 30 days with a hypothalamic hormone, alone or in combination with a pituitary hormone, or an agonist or antagonist, or a pituitary hormone or an agonist or antagonist thereof alone;
- (b) retrieving an oocyte(s) from the patient;
- (c) maturing the oocyte(s) in vitro, wherein during said maturation the oocyte(s) are exposed to a meiosis activating substance (MAS), and wherein the meiosis activating substance is a compound having a percentage germinal vesicle breakdown which is significantly higher than a control;
- and
- (d) fertilizing the in vitro matured oocyte(s).
Dependencies are inferred from the claim text.